News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TetraPhase Pharmaceuticals to Present Data at ICAAC Supporting its Lead Antibiotic Candidate Eravacycline’s Effectiveness Against Multi-drug Resistant (MDR) Pathogens


9/4/2013 7:18:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it will present at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) the results of important research that supports the potential of the company’s next-generation antibiotics portfolio, including its lead candidate eravacycline in the treatment of difficult-to-treat bacterial infections (e.g., serious Gram-negative and biothreat infections).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES